We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa (A-050)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02933281
Recruitment Status : Completed
First Posted : October 14, 2016
Last Update Posted : February 27, 2023
Sponsor:
Collaborators:
Biofabri, S.L
Universidad de Zaragoza
South African Tuberculosis Vaccine Initiative
Information provided by (Responsible Party):
International AIDS Vaccine Initiative

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
MTBVAC at four dose levels: 5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU. The active control is BCG (5 x 10^5 CFU). Participants will receive a single dose of MTBVAC or BCG revaccination administered intradermally on Study Day 0.

Condition or disease Intervention/treatment Phase
Tuberculosis Biological: MTBVAC Biological: BCG Phase 1 Phase 2

Detailed Description:

This is a Phase 1b/2a, double-blind, randomized, BCG-controlled, dose-escalation safety and immunogenicity study in 144 healthy adults with and without LTBI. All participants will have received previous BCG vaccination in infancy. The investigational product is MTBVAC at four dose levels: 5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU. The active control is BCG (5 x 10^5 CFU).

Participants meeting the inclusion/exclusion criteria will be randomized within a study cohort to receive a single dose of MTBVAC or BCG revaccination administered intradermally on Study Day 0. The study will be conducted at one site in South Africa. Participants will be enrolled into one of eight cohorts and followed for safety and immunogenicity endpoints through Study Day 365. The estimated time to complete enrolment is approximately 12 months.

Cohorts 1-8 will include 72 QFT-negative (Cohorts 1-4) and 72 QFT-positive (Cohorts 5-8) participants. Participants will be randomized within each cohort, to receive either MTBVAC (N=96) or BCG (N=48). The cohorts will be enrolled as described in the protocol, as long as no pausing/stopping rules are triggered

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled,Safety, Immunogenicity, and Dose-escalation Study in Adults With and Without Latent Tuberculosis Infection in South Africa
Actual Study Start Date : May 14, 2018
Actual Primary Completion Date : September 5, 2021
Actual Study Completion Date : September 5, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cohort 1: MTBVAC 5 x 10^3 CFU
Quantiferon (QFT) negative, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 2: MTBVAC 5 x 10^4 CFU
QFT Negative, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 3: MTBVAC 5 x 10^5 CFU
QFT Negative, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 4: MTBVAC 5 x 10^6 CFU
QFT Negative, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 5: MTBVAC 5 x 10^3 CFU
QFT Positive, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 6: MTBVAC 5 x 10^4 CFU
QFT Positive, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 7: MTBVAC 5 x 10^5 CFU
QFT Positive, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Experimental: Cohort 8: MTBVAC 5 x 10^6 CFU
QFT Positive, 1 dose on Day 0
 Biological: MTBVAC
Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
Active Comparator: BCG 5 x 10^5 CFU
Both QFT positive and negative, 1 dose on Day 0
 Biological: BCG
BCG 5 x 10^5 CFU
Other Name: BCG 5 x 10^5 CFU


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and reactogenicity of MTBVAC at escalating dose levels compared to BCG vaccine by assessing number of participants with AEs and SAEs [ Time Frame: Study Days 0 to Day 365 ]
    Collection of systemic solicited and unsolicited adverse events; solicited and unsolicited injection site reactions; and serious adverse reactions.


Secondary Outcome Measures :
  1. Difference in T cell response between MTBVAC dose levels across all post-immunization time points measured by percentage of MTBVAC-specific CD4 and CD8 T cells that produce any or a combination of relevant cytokines in ICS assay [ Time Frame: Study Days 0, 28, 56, 182, and 365 ]
    12 hour whole blood (WB) intracellular cytokine staining (ICS) assay

  2. Qualitative and quantitative results from QuantiFERON® TB (QFT) test summarized using participant count (percentage) summaries conversion and reversion rates in participants receiving escalating dose levels of MTBVAC [ Time Frame: Screening and Study Day 365 (all cohorts); and Study Days 28, 56, 84, and 182 (Cohorts 1-4) ]
    QFT Gold Plus assay

  3. Qualitative and quantitative results from QFT test using percentage conversion and reversion rates of participants receiving escalating dose levels of MTBVAC compared to BCG dose levels of MTBVAC in comparison to BCG measured by QFT Gold Plus assay [ Time Frame: Screening and Study Day 365 (all cohorts); and Study Days 28, 56, 84, and 182 (Cohorts 1-4) ]
    QFT Gold Plus assay


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  1. Has completed the written informed consent process.
  2. Is male or female aged 18 through 50 years on Study Day 0.
  3. Agrees to stay in contact with the clinical trial site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study.
  4. For female participants: agrees to avoid pregnancy from 21 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, or intrauterine device (IUD).
  5. For male participants: agrees to use barrier contraception with his partner for at least 2 weeks after dosing with MTBVAC or BCG.
  6. Has general good health, confirmed by medical history and physical examination.
  7. Had BCG vaccination, documented through medical history or presence of scar.
  8. Has not shared enclosed living or work space with someone diagnosed with TB during the 3 months prior to Study Day 0.
  9. [Cohorts 1-4] Does not have LTBI, determined by a negative QFT test at screening or [Cohorts 5-8] Has LTBI, determined by a positive QFT test at screening.

Exclusion Criteria

  1. Acute illness on Study Day 0.
  2. Axillary temperature >or= 37.5C on Study Day 0.
  3. Abnormal laboratory values from most recent blood collection prior to Study Day 0 randomization that are equivalent to Grade 2 or more toxicity, per the protocol toxicity table, or if deemed clinically significant.
  4. Severe anemia, defined as <10 g/dL hemoglobin or hematocrit <30%.
  5. Screening thyroid stimulating hormone (TSH) >upper limit of normal per local laboratory range.
  6. Suspicion or evidence (including but not limited to sputum Xpert MTB/RIF positive) of active TB disease at any site. An attempt must be made to obtain sputum from each participant; persons who are sputum unproductive will be assumed to be Xpert MTB/RIF negative.
  7. History of treatment for TB disease.
  8. History of autoimmune disease or immunosuppression.
  9. Used immunosuppressive medication within 42 days before Study Day 0 (inhaled and topical corticosteroids are permitted).
  10. Received immunoglobulin or blood products within 42 days before Study Day 0.
  11. Received any investigational drug or investigational vaccine within 182 days before Study Day 0, or planned participation in any other investigational study during the study period.
  12. Received investigational vaccine against TB at any time prior to Study Day 0.
  13. Planned administration/administration of a licensed vaccine in the period starting 28 days before and ending 28 days after dosing with investigational product.
  14. History or laboratory evidence of any past, present, or future possible immunodeficiency state including but not limited to any laboratory indication of HIV-1 infection.
  15. History of allergic disease or reactions, including eczema, likely to be exacerbated by any component of the investigational product.
  16. Previous medical history that may compromise the safety of the participant in the study, including but not limited to: impairment of pulmonary function from TB infection or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease; uncontrolled epilepsy or infantile spasms; or diabetes mellitus.
  17. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine, including axillary lymphadenopathy.
  18. Female participants: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening or pre-vaccination on Study Day 0.
  19. Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, could endanger the participant or make it unlikely that the participant will comply with the protocol.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933281


Locations
Layout table for location information
South Africa
SATVI: Worcester
Worcester, South Africa, 6850
Sponsors and Collaborators
International AIDS Vaccine Initiative
Biofabri, S.L
Universidad de Zaragoza
South African Tuberculosis Vaccine Initiative
Investigators
Layout table for investigator information
Principal Investigator: Angelique Luabeya, MD SATVI
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier: NCT02933281    
Other Study ID Numbers: A-050
First Posted: October 14, 2016    Key Record Dates
Last Update Posted: February 27, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Latent Tuberculosis
Infections
Mycobacterium Infections
Actinomycetales Infections
 Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Latent Infection